Moderna (MRNA) Income towards Parent Company (2017 - 2026)

Moderna (MRNA) has reported Income towards Parent Company for 10 consecutive years, with -$782.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Income towards Parent Company rose 5.21% year-over-year to -$782.0 million in Q2 2026; TTM through Jun 2026 was -$3.2 billion, a 8.54% decrease from a year earlier, with the FY2025 full-year figure at -$2.8 billion, up 20.75% from the prior year.
• Income towards Parent Company was -$782.0 million for Q2 2026 at Moderna, up from -$1.3 billion in the prior quarter.
• Over five years, Income towards Parent Company peaked at $3.7 billion in Q1 2022 and troughed at -$3.6 billion in Q3 2023.
• A 5-year average of -$270.0 million and a median of -$803.5 million in 2025 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company surged 199.51% in 2022 and sank 1638.46% in 2025, its largest moves.
• Over 5 years, Income towards Parent Company stood at $1.5 billion in 2022, then sank by 85.19% to $217.0 million in 2023, then tumbled by 616.13% to -$1.1 billion in 2024, then rose by 26.25% to -$826.0 million in 2025, then rose by 5.33% to -$782.0 million in 2026.
• The last three Income towards Parent Company figures came in at -$782.0 million (Q2 2026), -$1.3 billion (Q1 2026), and -$826.0 million (Q4 2025), per Business Quant data.